Stoke Therapeutics (NASDAQ:STOK) Receives New Coverage from Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. started coverage on shares of Stoke Therapeutics (NASDAQ:STOK) in a research note released on Monday morning, BenzingaRatingsTable reports. The firm issued an overweight rating and a $34.00 price objective on the stock.

Separately, Cowen restated a buy rating on shares of Avrobio in a research note on Monday.

Shares of NASDAQ:STOK opened at $23.89 on Monday. Stoke Therapeutics has a 12-month low of $22.84 and a 12-month high of $31.76.

In other Stoke Therapeutics news, major shareholder Rtw Investments, Lp bought 555,556 shares of the stock in a transaction on Wednesday, June 19th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $10,000,008.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Apple Tree Partners Iv, L.P. bought 1,388,889 shares of the stock in a transaction on Friday, June 21st. The shares were acquired at an average price of $18.00 per share, with a total value of $25,000,002.00. The disclosure for this purchase can be found here.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.

Recommended Story: Hedge Funds Explained

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with's FREE daily email newsletter.